Abdera Therapeutics
Raymond W. is an experienced finance professional currently serving as Director of Finance at Abdera Therapeutics since July 2024. Prior to this role, Raymond held several key positions in financial planning and analysis, including Director and Associate Director of Financial Planning & Analysis at Allakos Inc between December 2021 and June 2024. Previous experience also includes Associate Director roles in Pricing & Contracting at Myovant Sciences and Aimmune Therapeutics, along with a Sr. Manager position at Dermira, Inc. In earlier roles, Raymond gained valuable experience as Finance Manager at Genentech and Walmart eCommerce, and various finance positions at Sears Holdings Corporation, starting as an Inventory Analyst and progressing to Business Finance Manager. Raymond holds a degree from the University of Florida.
This person is not in any offices
Abdera Therapeutics
1 followers
Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers. Its targeted radiotherapies utilize purpose-built vectors to specifically target high-energy radio-isotopes to tumors and metastatic cancer lesions. This new class of drugs holds tremendous untapped therapeuticand commercial potential, and has generated over $10B in recent M&A, financings, and product launches – and are expected to comprise 70% of the $30B nuclear medicine market by 2030.It was launched by adMare BioInnovations, Canada’s global life sciences venture, in partnership with industry leaders AbCellera, and some of the country’s most successful scientist entrepreneurs.